ORIC · Oric Pharmaceuticals, Inc.

The shares subject to the option are fully vested and immediately exercisable.

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.

The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.

The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2025.

Represents the weighted average share price of an aggregate total of 52,000 shares sold in the price range of $13.50 to $13.53 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.

Represents the weighted average share price of an aggregate total of 6,700 shares sold in the price range of $12.00 to $12.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.

Represents the weighted average share price of an aggregate total of 6,700 shares sold in the price range of $12.00 to $12.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.

1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.

1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.

1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028.

25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.

1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028.

1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.

25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.

25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.

1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.

1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028.

Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.

Represents the weighted average share price of an aggregate total of 10,720 shares sold in the price range of $9.0396 to $9.1953 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.

Represents the weighted average share price of an aggregate total of 33,374 shares sold in the price range of $9.0257 to $9.095 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.

Represents the weighted average share price of an aggregate total of 10,720 shares sold in the price range of $9.0449 to $9.1451 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

Includes an aggregate of 2,771 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

Includes 1,218 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant.

(A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B) one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022.

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2025.

Represents the weighted average share price of an aggregate total of 11,000 shares sold in the price range of $14.50 to $14.53 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2025.

Represents the weighted average share price of an aggregate total of 37,461 shares sold in the price range of $12.07 to $12.59 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number.

The shares subject to the option are fully vested and immediately exercisable.

The shares subject to the option are fully vested and immediately exercisable.

The shares subject to the option are fully vested and immediately exercisable.

The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2025.

Represents the weighted average share price of an aggregate total of 53,001 shares sold in the price range of $12.00 to $12.13 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number.